Evelo Biosciences Competitors

Evelo Biosciences (NASDAQ:EVLO) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares Evelo Biosciences and Xencor's revenue, earnings per share and valuation.

Xencor has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Evelo Biosciences and Xencor, as reported by MarketBeat.com.

Evelo Biosciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.01%. Xencor has a consensus price target of $47.1111, suggesting a potential upside of 11.48%. Given Evelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Evelo Biosciences is more favorable than Xencor.

Profitability

This table compares Evelo Biosciences and Xencor's net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 3.7% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Evelo Biosciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Summary

Evelo Biosciences beats Xencor on 7 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and ALX Oncology (NASDAQ:ALXO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Evelo Biosciences and ALX Oncology, as reported by MarketBeat.com.

Evelo Biosciences currently has a consensus price target of $20.00, suggesting a potential upside of 73.01%. ALX Oncology has a consensus price target of $90.6667, suggesting a potential upside of 49.29%. Given Evelo Biosciences' higher possible upside, equities analysts plainly believe Evelo Biosciences is more favorable than ALX Oncology.

Profitability

This table compares Evelo Biosciences and ALX Oncology's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Evelo Biosciences and ALX Oncology's top-line revenue, earnings per share and valuation.

Institutional and Insider Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 73.5% of ALX Oncology shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ALX Oncology beats Evelo Biosciences on 4 of the 7 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and Evelo Biosciences (NASDAQ:EVLO) are both transportation companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Cryoport has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cryoport and Evelo Biosciences, as provided by MarketBeat.com.

Cryoport currently has a consensus target price of $72.00, suggesting a potential upside of 39.62%. Evelo Biosciences has a consensus target price of $20.00, suggesting a potential upside of 73.01%. Given Evelo Biosciences' higher possible upside, analysts clearly believe Evelo Biosciences is more favorable than Cryoport.

Earnings & Valuation

This table compares Cryoport and Evelo Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Cryoport has higher revenue and earnings than Evelo Biosciences. Cryoport is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cryoport and Evelo Biosciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

88.3% of Cryoport shares are held by institutional investors. Comparatively, 84.6% of Evelo Biosciences shares are held by institutional investors. 11.5% of Cryoport shares are held by insiders. Comparatively, 7.3% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cryoport beats Evelo Biosciences on 9 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Evelo Biosciences and Arcus Biosciences' net margins, return on equity and return on assets.

Risk and Volatility

Evelo Biosciences has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Insider & Institutional Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 19.7% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Evelo Biosciences and Arcus Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Arcus Biosciences has higher revenue and earnings than Evelo Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Evelo Biosciences and Arcus Biosciences, as provided by MarketBeat.

Evelo Biosciences presently has a consensus target price of $20.00, indicating a potential upside of 73.01%. Arcus Biosciences has a consensus target price of $51.50, indicating a potential upside of 55.45%. Given Evelo Biosciences' higher probable upside, equities research analysts clearly believe Evelo Biosciences is more favorable than Arcus Biosciences.

Summary

Arcus Biosciences beats Evelo Biosciences on 8 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Insider and Institutional Ownership

84.6% of Evelo Biosciences shares are owned by institutional investors. 7.3% of Evelo Biosciences shares are owned by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Evelo Biosciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Evelo Biosciences and Prestige Consumer Healthcare's top-line revenue, earnings per share (EPS) and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Evelo Biosciences and Prestige Consumer Healthcare, as provided by MarketBeat.com.

Evelo Biosciences presently has a consensus price target of $20.00, indicating a potential upside of 73.01%. Prestige Consumer Healthcare has a consensus price target of $87.60, indicating a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Evelo Biosciences.

Profitability

This table compares Evelo Biosciences and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Summary

Prestige Consumer Healthcare beats Evelo Biosciences on 8 of the 12 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Evelo Biosciences and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Evelo Biosciences and Dicerna Pharmaceuticals, as reported by MarketBeat.

Evelo Biosciences currently has a consensus target price of $20.00, indicating a potential upside of 73.01%. Dicerna Pharmaceuticals has a consensus target price of $39.1429, indicating a potential upside of 35.16%. Given Evelo Biosciences' higher possible upside, equities research analysts clearly believe Evelo Biosciences is more favorable than Dicerna Pharmaceuticals.

Risk & Volatility

Evelo Biosciences has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Evelo Biosciences and Dicerna Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Evelo Biosciences has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Dicerna Pharmaceuticals beats Evelo Biosciences on 7 of the 13 factors compared between the two stocks.